Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Johnson & Johnson (JNJ) Stock Price & Analysis

JNJ Stock Chart & Stats

MX$5,167.40-MX$20.83(-0.40%)
At close:
MXN 4,500MXN 4,750MXN 5,0003 Aug17 Aug31 Aug15 Sep28 Sep12 Oct26 Oct
Day’s Range
MXN 5,167.40 - MXN 5,240.79
52-Week Range
MXN 3,410.01 - MXN 5,240.79
Previous Close
MXN 5,188.23
Volume
77
Average Volume (3M)
924
Market Cap
MXN 12.36T
Enterprise Value
MXN 691.53B
Total Cash (Recent Filing)
MXN 17.23B
Total Debt (Recent Filing)
MXN 44.65B
Price to Earnings (P/E)
41.4
Beta
-0.18
Next Earnings
Jan 26, 2027 (Est.)
EPS Estimate
53.85
Next Dividend Ex-Date
N/A
Dividend Yield
1.73%

Bulls Say, Bears Say

Bulls Say

Innovative Medicine Growth

Strong growth across oncology, immunology, neuroscience, and other therapeutic areas indicates broad product adoption rather than dependence on a single medicine. Multiple expanding brands can sustain revenue momentum, support reinvestment, and help offset future product-level erosion.

Reliable Cash Generation

Consistently positive operating and free cash flow gives Johnson & Johnson substantial capacity to fund research, business development, dividends, and debt service internally. This recurring cash engine strengthens resilience and supports continued investment through changing healthcare cycles.

Innovation And Portfolio Expansion

Investment in next-generation oncology platforms expands the pipeline beyond current products and targets difficult-to-treat cancers with significant unmet need. Although costly initially, these capabilities can reinforce Johnson & Johnson’s long-term competitive position and future growth options.

Bears Say

Margin Pressure

The decline in adjusted margins shows that product mix, amortization, research spending, and transaction costs are currently absorbing part of the company’s operating leverage. Persistent pressure would reduce the amount of revenue growth converting into earnings and cash.

Higher Debt And Slower Free Cash Flow

Higher debt alongside weaker recent free-cash-flow growth reduces financial flexibility compared with prior lower-leverage periods. The balance sheet remains generally sound, but less conservative coverage can constrain capital allocation and increase sensitivity to execution or transaction costs.

Biosimilar Erosion

STELARA’s decline demonstrates how biosimilar competition can erode established pharmaceutical revenue after exclusivity weakens. Continued pressure on mature franchises could offset newer-product growth, requiring sustained pipeline productivity and commercial execution to preserve overall expansion.

Johnson & Johnson News

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was Mex$3410.01 and its highest was Mex$5240.79 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is Mex$12.36T.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s next earnings report is estimated for Jan 26, 2027 (not yet confirmed), which is in 85 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Oct 13, 2026. The company reported Mex$48.056 earnings per share for the quarter, beating the consensus estimate of Mex$46.795 by Mex$1.262.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson does not currently pay dividends.
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 53.85.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,310,300 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of Mex$48.056 in its last earnings report, beating expectations of Mex$46.795. Following the earnings report the stock price went down -4.623%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Hedge funds hold Johnson & Johnson shares: hedge funds increased their holdings by 3.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology